Endometriose: medikamentöse Rezidivprophylaxe nach Laparoskopie

Judith Lorenz
In: Frauenheilkunde up2date · 2024 · vol. 18(01) , pp. 10–11 · doi:10.1055/a-2211-3391 · W4392787212
RCT OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-01 ⓘ

This Iranian randomized controlled study evaluated the efficacy of dienogest and medroxyprogesterone acetate in preventing endometriosis recurrence and alleviating clinical symptoms following laparoscopic surgery.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-24 · read from full text ⓘ

This paper reviews a randomized controlled trial conducted in Iran to evaluate the efficacy of Dienogest and Medroxyprogesterone acetate (MPA) in preventing endometriosis recurrence after laparoscopic surgery. The study specifically assessed how well these two progestins protect against the development of new lesions and their ability to alleviate clinical symptoms associated with the disease. While the abstract highlights the research question regarding the comparative benefits of these hormonal treatments, it does not detail specific numerical outcomes or statistical significance within the provided text. This paper is centrally about endometriosis — specifically focusing on medical prophylaxis for recurrence following surgical intervention.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Ein erheblicher Anteil der Frauen, die sich aufgrund einer Endometriose einem laparoskopischen chirurgischen Eingriff unterziehen, entwickelt im Verlauf erneut Endometrioseläsionen. Wie gut schützen Dienogest und Medroxyprogesteronacetat (MPA) vor solchen Rezidiven? Und wie gut lindern die beiden Wirkstoffe die klinischen Symptome? Diesen Fragen ging eine randomisierte kontrollierte Studie aus dem Iran nach.
Full text 901 characters · extracted from oa-doi-fallback · click to expand
Subscribe to RSS Please copy the URL and add it into your RSS Feed Reader. https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000142.xml Frauenheilkunde up2date 2024; 18(01): 10-11 DOI: 10.1055/a-2211-3391 DOI: 10.1055/a-2211-3391 Studienreferate Endometriose: medikamentöse Rezidivprophylaxe nach Laparoskopie Authors Ein erheblicher Anteil der Frauen, die sich aufgrund einer Endometriose einem laparoskopischen chirurgischen Eingriff unterziehen, entwickelt im Verlauf erneut Endometrioseläsionen. Wie gut schützen Dienogest und Medroxyprogesteronacetat (MPA) vor solchen Rezidiven? Und wie gut lindern die beiden Wirkstoffe die klinischen Symptome? Diesen Fragen ging eine randomisierte kontrollierte Studie aus dem Iran nach. Publication History Article published online: 13 February 2024 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

die_deep_infiltrating

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-11-14T06:25:03.947826+00:00
License: CC0 · commercial use OK